推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 全國政協(xié)委員、中國工程院院士吳以嶺近日在提案中建議，遏制中藥材價(jià)格上漲過快，保護(hù)中醫(yī)藥行業(yè)。
吳以嶺說，盡管近兩年大多數(shù)中藥材價(jià)格有所降低，但與之前相比，有70%～80%常用中藥材的價(jià)格上漲超過兩倍。“必須正視中藥材價(jià)格近年快速上漲對整個(gè)中醫(yī)藥產(chǎn)業(yè)發(fā)展造成的嚴(yán)重影響。”
在他看來，首先，患者服用中藥的消費(fèi)成本提高，不利于中醫(yī)藥在基層的推廣應(yīng)用；其次，中藥企業(yè)面臨生產(chǎn)成本上漲的巨大壓力，許多效高價(jià)低的產(chǎn)品要么縮減產(chǎn)量、要么直接停產(chǎn)，個(gè)別企業(yè)甚至可能在原材料方面偷工減料，對中藥產(chǎn)業(yè)發(fā)展極為不利；第三，過高的藥材價(jià)格帶來的利益誘惑，使中藥材資源過度采伐；第四，價(jià)格過高使制假售假者眾多，老百姓深受其害。
為此，他建議，對資源稀缺和能人工種養(yǎng)殖的中藥品種給予資金、技術(shù)、政策支持。對于影響國家環(huán)境與生態(tài)的不可再生品種，尋求替代品種，并有組織地在藥典中明確。同時(shí)，盡快建立并不斷完善中藥材收儲(chǔ)制度，實(shí)現(xiàn)國家對大宗中藥材品種的收儲(chǔ)管理。
